PMLive

AstraZeneca’s Enhertu combination approved by FDA for HER2-positive breast cancer

AstraZeneca and Daiichi Sankyo’s Enhertu, in combination with pertuzumab, has been approved by the US FDA to treat adult ...
Pharmabiz

US FDA approves AstraZeneca and Daiichi Sankyo’s Enhertu plus pertuzumab for 1st-line treatment of patients with HER2-positive metastatic breast cancer

US FDA approves AstraZeneca and Daiichi Sankyo’s Enhertu plus pertuzumab for 1st-line treatment of patients with HER2-positive metastatic breast cancer: Cambridge, UK Wednesday, ...

Compugen rises on royalty deal with AstraZeneca

Shares of Compugen (CGEN) added ~16% in the premarket on Wednesday after the Israel-based biotech announced an agreement with ...

Breast Cancer Drugs Market to Reach USD 57.1 Billion by 2031 as Precision Oncology and Targeted Therapies Redefine Treatment Outcomes

According to DataM Intelligence, the global Breast Cancer Drugs Market reached USD 32.4 billion in 2024 and is projected to ...